Nucleosomes containing histone type 3.1 – new predictor of complications in patients with ST elevation myocardial infarction

Authors: Fomenko A.N.1, Zaigraev I.A.1 2, Krotenko N.P., 1 Em Yu.S.1, Dadaev V.S.1, Doronenkova А.А.1

Company: 1 S.S. Yudin City Clinical Hospital, Moscow, Russian Federation
2 National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Original articles


DOI: https://doi.org/10.24022/1997-3187-2024-18-2-183-193

For citation: Fomenko A.N., Zaigraev I.A., Krotenko N.P., Em Yu.S., Dadaev V.S., Doronenkova А.А. Nucleosomes containing his- tone type 3.1 – new predictor of complications in patients with ST elevation myocardial infarction. Creative Cardiology. 2024; 18 (2): 183–193 (in Russ.). DOI: 10.24022/1997-3187-2024-18-2-183-193

Received / Accepted:  02.04.2024 / 08.05.2024

Keywords: acute coronary syndrome with ST-segment elevation percutaneous coronary intervention nucleosomes containing histone type 3.1 netosis troponin I arrhythmia acute left ventricular failure acute cardiovascular failure Killip



Subscribe 🔒

 

Abstract

Objective. Evaluate associations nucleosomes containing histone type 3.1 (nucleosomes H3.1) with complications of ST elevation myocardial infarction (STEMI).

Material and methods. It was prospective single-center observational pilot study included 44 patients with STEMI admitted to cardiоvacular intensive care unit during may-august 2023.We were measured nucleosomes H3.1on admission and 24 hours after percutaneous coronary intervention (PCI). Associations nucleosomes H3.1 before and after the PCI. estimated with significant complications and conditions in patients with STEMI – death, acute left ventricular failure (ALVF), acute cardiovascular failure (ACF), arrhythmya, high Killip classes.

Results. The average age of patients was 60.6 ± 9.6 years. The most common complications were: cardiogenic shock (18.4%), arrhythmia (16.9%). Killip II–IV classes was observed in 20.4%. Initial level nucleosomes H3.1 at admission (33.0 (15.8–101.3)) ng/ml and after PCI (65.0 (25.0–188.0)), no statistically significant differences (p = 0.18).

The areas under the characteristic curve for nucleosomes H3.1 before and after PCI determined significantly associations with ALVF, Killip stage II–IV and arrhythmia, ACF respectively. Value of the level Nuk. H3.1 before PCI ≥49 and ≥39 ng/ ml, the risk of ALVF and the development of Killip grades 2–4 increased 16.2 times (95% CI (1.73–151.85) p = 0.006) and 4.7 times (95% CI 1.04–21.01) p = 0.04), respectively, and the concentration of Nuk. H3.1 after PCI ≥59 ng/ml increased the risk of arrhythmia and ACF by 1.5 times (95% CI 1.1–2.0, p = 0.018 and 95% CI 1.1–1.8, p = 0.03, respectively). 

Conclusion. In the studied group of patients with STEMI, higher level of Nuk. H3.1 before and after PCI were associated with ALVF, Killip stage 2–4 and arrhythmia, ACF respectively.

References

  1. Ibanez B., James S., Agewall S., Antunes M., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018; 39 (2): 119–177. DOI: 10.1093/eurheartj/ehx393
  2. Grabuschnig S., Bronkhorst A., Holdenrieder S., Rosales Rodriguez I., Schliep K., Schwendenwein D. et al. Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms. Int. J. Mol. Sci. 2020; 21 (21): 8062. DOI: 10.3390/ijms21218062
  3. Polina I., Ilatovskaya D., DeLeon-Pennell K. Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. Clin. Chim. Acta. 2020; 503: 145–150. DOI: 10.1016/j.cca.2020.01.013
  4. Mandel P., Metais P., Les acides nucléiques du plasma sanguin chez l’homme [Nuclear acids in human blood plasma]. C R Seances Soc. Biol. Fil. 1948; 142 (3–4): 241–3 (in French).
  5. Döring Y., Libby P., Soehnlein O. Neutrophil extracellular traps participate in cardiovascular diseases: recent experimental and clinical insights. Circ. Res. 2020; 126 (9): 1228–1241. DOI: 10.1161/CIRCRESAHA.120.315931
  6. Mangold A., Alias S., Scherz T. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. Circ. Res. 2015; 116 (7): 1182–1192. DOI: 10.1161/CIRCRESAHA.116.304944
  7. Tian Y., Charles E.J., Yan Z., Wu D., French B.A., Kron I.L., Yang Z. The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1-receptor for advanced glycation end products-Toll-like receptor 9 pathway. J. Thorac. Cardiovasc. Surg. 2019; 157 (6): 2256–2269.e3. DOI: 10.1016/j.jtcvs.2018.09.043
  8. Wu B., Ni H., Li J., Zhuang X., Zhang J., Qi Z., Chen Q. et al. The impact of circulating mitochondrial DNA on cardiomyocyte apoptosis and myocardial injury after TLR4 activation in experimental autoimmune myocarditis. Cell. Physiol. Biochem. 2017; 42 (2): 713–728. DOI: 10.1159/000477889
  9. Tan E., Liu D., Perry L., Zhu J., Cid-Serra X., Deane A., Yeo C., Ajani A. Cell-free DNа as a potential biomarker for acute myocardial infarction: а systematic review and meta-analysis. Int. J. Cardiol. Heart Vasc. 2023; 47: 101246. DOI: 10.1016/j. ijcha.2023.101246
  10. Cui M., Fan M., Jing R., Wang H., Qin J., Sheng H. et al. Cell-Free circulating DNA: a new biomarker for the acute coronary syndrome. Cardiology. 2013; 124 (2): 76–84. DOI: 10.1159/000345855
  11. Shimony A., Zahger D., Gilutz H., Goldstein H., Orlov G., Merkin M. et al. Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card Care. 2010; 12 (3): 109–111. DOI: 10.3109/17482941.2010.513732
  12. Helseth R., Solheim S., Arnesen H., Seljeflot I., Opstad T.B. The time course of markers of neutrophil extracellular traps in patients undergoing revascularisation for acute myocardial infarction or stable angina pectoris. Mediat. Inflamm. 2016; 2016: 2182358. DOI: 10.1155/2016/2182358
  13. Langseth M.S., Opstad T.B., Bratseth V., Solheim S., Arnesen H., Pettersen A.Å. et al. Markers of neutrophil extracellular traps are associated with adverse clinical outcome in stable coronary artery disease. Eur. J. Prev. Cardiol. 2018; 25 (7): 762–769. DOI: 10.1177/2047487318760618
  14. Liu J., Yang D., Wang X., Zhu Z., Wang T., Ma A., Liu P. Neutrophil extracellular traps and dsDNA predict outcomes among patients with ST-elevation myocardial infarction. Sci. Rep. 2019; 9 (1): 11599. DOI: 10.1038/s41598-019-47853-7
  15. Borissoff J.I., Joosen I.A., Versteylen M.O., Brill A., Fuchs T.A., Savchenko A.S. еt al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler. Thromb. Vasc. Biol. 2013; 33 (8): 2032–2040. DOI: 10.1161/ATVBAHA.113.301627
  16. Haem Rahimi M., Bidar F., Lukaszewicz A.C., Garnier L., Payen-Gay L., Venet F., Monneret G. Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock. Ann. Intensive Care. 2023; 13 (1): 102. DOI: 10.1186/s13613-023-01204-y

About Authors

  • Anatoliy N. Fomenko, Anesthesiologist-Intensivist; ORCID
  • Ivan A. Zaigraev, Therapist, Junior Researcher; ORCID
  • Nikolay P. Krotenko, Cand. Med. Sci., Anesthesiologist-Intensivist, Head of Department; ORCID
  • Yuriy S. Em, Anesthesiologist-Intensivist, Head of Department; ORCID
  • Vitaliy S. Dadaev, Anesthesiologist-Intensivist; ORCID
  • Anastasiya A. Doronenkova, Anesthesiologist-Intensivist; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery